Louai Labanieh
YOU?
Author Swipe
View article: Engineered CD47 protects T cells for enhanced antitumour immunity
Engineered CD47 protects T cells for enhanced antitumour immunity Open
View article: Directed evolution of genetically encoded LYTACs for cell-mediated delivery
Directed evolution of genetically encoded LYTACs for cell-mediated delivery Open
Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versions of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here, we pre…
View article: Inosine induces stemness features in CAR-T cells and enhances potency
Inosine induces stemness features in CAR-T cells and enhances potency Open
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8+ CAR-T cells express CD39 and CD73, which mediate proximal steps in Ado generation. Here, we sought to enhance CAR-T cell potency by kno…
View article: Directed Evolution of Genetically Encoded LYTACs for Cell-Mediated Delivery
Directed Evolution of Genetically Encoded LYTACs for Cell-Mediated Delivery Open
Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versions of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here we pres…
View article: 275 Inosine endows CAR T cells with features of increased stemness and anti-tumor potency
275 Inosine endows CAR T cells with features of increased stemness and anti-tumor potency Open
Background CAR T cells have been highly effective against refractory B cell malignancies but have not demonstrated sustained antitumor effects against solid tumors. Intense effort is underway to augment the potency of CAR T cells in order …
View article: Engineered CD47 protects T cells for enhanced antitumor immunity
Engineered CD47 protects T cells for enhanced antitumor immunity Open
Adoptively transferred T cells and agents designed to block the CD47/SIRPα axis are promising antitumor therapeutics, which activate distinct arms of the immune system. We administered anti-CD47 (αCD47) with adoptively transferred T cells …
View article: Author Correction: CAR immune cells: design principles, resistance and the next generation
Author Correction: CAR immune cells: design principles, resistance and the next generation Open
View article: Inosine Induces Stemness Features in CAR T cells and Enhances Potency
Inosine Induces Stemness Features in CAR T cells and Enhances Potency Open
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8 + CAR T cells mediate Ado-induced immunosuppression through CD39/73-dependent Ado production. Knockout of CD39, CD73 or A2aR had modest effects on …
View article: Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
Data from Tuning the Antigen Density Requirement for CAR T-cell Activity Open
Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold for antigen recognition. We de…
View article: Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
Data from Tuning the Antigen Density Requirement for CAR T-cell Activity Open
Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold for antigen recognition. We de…
View article: Supplementary Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
Supplementary Data from Tuning the Antigen Density Requirement for CAR T-cell Activity Open
Supplemental Table 1 Supplementary Figures 1-10
View article: Supplementary Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
Supplementary Data from Tuning the Antigen Density Requirement for CAR T-cell Activity Open
Supplemental Table 1 Supplementary Figures 1-10
View article: Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors Open
Purpose:Patients with relapsed pediatric solid tumors and CNS malignancies have few therapeutic options and frequently die of their disease. Chimeric antigen receptor (CAR) T cells have shown tremendous success in treating relapsed pediatr…
View article: Figure S2 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S2 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S2 shows characterization of B7H3-sr39tk CAR phenotypic subsets
View article: Data from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Data from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Imaging strategies to monitor chimeric antigen receptor (CAR) T-cell biodistribution and proliferation harbor the potential to facilitate clinical translation for the treatment of both liquid and solid tumors. In addition, the potential ad…
View article: Figure S2 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S2 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S2 shows characterization of B7H3-sr39tk CAR phenotypic subsets
View article: Figure S4 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S4 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S4 shows long-term monitoring of mice following GCV treatment, confirming persistent T-cell ablation
View article: Figure S3 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S3 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
FIgure S3 shows B7H3 CAR expression of remaining viable B7H3-sr39tk CAR T-cells after GCV treatment
View article: Data from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Data from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Imaging strategies to monitor chimeric antigen receptor (CAR) T-cell biodistribution and proliferation harbor the potential to facilitate clinical translation for the treatment of both liquid and solid tumors. In addition, the potential ad…
View article: Figure S3 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S3 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
FIgure S3 shows B7H3 CAR expression of remaining viable B7H3-sr39tk CAR T-cells after GCV treatment
View article: Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors Open
Purpose:Patients with relapsed pediatric solid tumors and CNS malignancies have few therapeutic options and frequently die of their disease. Chimeric antigen receptor (CAR) T cells have shown tremendous success in treating relapsed pediatr…
View article: Figure S1 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S1 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S1 shows Surface B7H3 CAR, PD-1, and LAG-3 expression of T-cells transduced with CAR retroviral supernatant
View article: Figure S4 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S4 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S4 shows long-term monitoring of mice following GCV treatment, confirming persistent T-cell ablation
View article: Supplementary Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Supplementary Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors Open
Supplementary Figures
View article: Figure S5 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S5 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S5 shows flow cytometry of spleens at 9 days following the final GCV treatment
View article: Figure S5 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S5 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S5 shows flow cytometry of spleens at 9 days following the final GCV treatment
View article: Figure S1 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors
Figure S1 from PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors Open
Figure S1 shows Surface B7H3 CAR, PD-1, and LAG-3 expression of T-cells transduced with CAR retroviral supernatant
View article: Supplementary Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Supplementary Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors Open
Supplementary Figures
View article: Co-opting signalling molecules enables logic-gated control of CAR T cells
Co-opting signalling molecules enables logic-gated control of CAR T cells Open
View article: 352 STASH select, a simple and robust method of purifying cells engineered with multiple vectors using a single selection marker
352 STASH select, a simple and robust method of purifying cells engineered with multiple vectors using a single selection marker Open
Background CAR-T cell therapies have demonstrated remarkable clinical benefit in liquid tumors, but significant obstacles such as antigen loss, tumor heterogeneity, T cell exhaustion, and poor persistence limit the frequency and durability…